Thomas Stöhr, PhD, is co-founder and managing director of A2M Pharma, a spin-off from the former Schwarz Pharma. He has more than 15 years experience in drug discovery and development and helped to bring several drugs and medical devices to the market. He is a trained CNS pharmacologist and gained a lot of experience in preclinical and early clinical development of drugs for the treatment of neurological, immunological and infectious diseases.